Drug intelligence / Profile preview

CMA-100

Development stage: Preclinical
Lead developer: Life Biosciences
Modality: Small Molecules

Overview

CMA-100 is a preclinical **small-molecule autophagy stimulant** being developed by Life Biosciences for nervous system disease, with public pipeline-style sources specifically linking it to **Alzheimer's disease**. Publicly available information does not identify a disclosed INN, brand name, chemical structure, or precise molecular target; the available description supports only that it is intended to enhance autophagy biology, likely within Life Biosciences' broader chaperone-mediated autophagy program, as an approach to reduce age-related proteostatic dysfunction relevant to neurodegeneration.

Beyond the preview

Go deeper on CMA-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMA-100.

Explore the full profile